Bevacizumab in therapy-refractory epistaxis. Case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia

被引：2
作者：
Rohrmeier, C. [1 ]
Kuehnel, T. S. [1 ]
机构：
[1] Univ Klinikum Regensburg, Klin Hals Nasen Ohren Heilkunde Kopf & Halschirur, D-93053 Regensburg, Germany
来源：
HNO | 2012年 / 60卷 / 11期
关键词：
Hereditary hemorrhagic telangiectasia; Osler disease; Bevacizumab; Epistaxis; Case report;
D O I：
10.1007/s00106-011-2458-x
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
We report on the submucosal injection of bevacizumab (Avastin) at a dose of 0.3 to 3.75 mg per side in a patient with hereditary hemorrhagic telangiectasia. Application of such low doses has not been described in the literature yet. Our case report shows the positive effect of low-dose bevacizumab on therapy-refractory epistaxis. No complications were caused by the bevacizumab treatment.
引用
收藏
页码：1003 / 1006
页数：4
相关论文
共 46 条
  • [1] Bevacizumab bei therapierefraktärer EpistaxisFallbericht einer niedrigdosierten, submukös injizierten Antikörpertherapie bei M. OslerBevacizumab in therapy-refractory epistaxisCase report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia
    C. Rohrmeier
    T.S. Kühnel
    HNO, 2012, 60 : 1003 - 1006
  • [2] Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia
    Huemer, Florian
    Dejaco, Martin
    Grabmer, Christoph
    Melchardt, Thomas
    Neureiter, Daniel
    Mayer, Georg
    Egle, Alexander
    Greil, Richard
    Weiss, Lukas
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (3-4) : 141 - 144
  • [3] Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia
    Kochanowski, J.
    Sobieszczanska, M.
    Tubek, S.
    Zurek, M.
    Pawelczak, J.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (03) : 680 - 681
  • [4] Hereditary hemorrhagic telangiectasia with epistaxis: a case report
    Oziris, Mahmut
    ERCIYES MEDICAL JOURNAL, 2007, 29 (03) : 239 - 241
  • [5] Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy
    Karnezis, Tom T.
    Davidson, Terence M.
    LARYNGOSCOPE, 2012, 122 (03) : 495 - 497
  • [6] Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasiaA case report
    Florian Huemer
    Martin Dejaco
    Christoph Grabmer
    Thomas Melchardt
    Daniel Neureiter
    Georg Mayer
    Alexander Egle
    Richard Greil
    Lukas Weiss
    Wiener klinische Wochenschrift, 2017, 129 : 141 - 144
  • [7] Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia
    Jameson, JJ
    Cave, DR
    LARYNGOSCOPE, 2004, 114 (04) : 705 - 709
  • [8] Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab
    Wee, Jee Wan
    Jeon, Young Woo
    Eun, Jun Young
    Kim, Han Jo
    Bae, Sang Byung
    Lee, Kyu Taek
    BLOOD RESEARCH, 2014, 49 (03) : 192 - 195
  • [9] Acute exacerbation of recurrent epistaxis and anemia in hereditary hemorrhagic telangiectasia: A case report
    Li, Ting
    Ma, Juan
    Zhang, Hailing
    Huang, Yan
    ASIAN JOURNAL OF SURGERY, 2024, 47 (09) : 4104 - 4105
  • [10] Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report
    Ospina, Fabio E.
    Echeverri, Alex
    Posso-Osorio, Ivan
    Jaimes, Lina
    Gutierrez, Jaiber
    Tobon, Gabriel J.
    COLOMBIA MEDICA, 2017, 48 (02): : 88 - 93
12345